AGLE News and Press, Aeglea BioTherapeutics Inc. From 02/10/22

Aeglea BioTherapeutics (AGLE -6.5%) is trading lower for the third straight session after announcing that Sara Brownstein, a Class I director of its Board, informed the company on Wednesday that she would resign, effective Feb. 09. “The Company believes Ms. Brownstein’s resignat...

Gainers: Dermata Therapeutics (NASDAQ:DRMA) +35%. Innoviva (NASDAQ:INVA) +11%. Mainz Biomed (NASDAQ:MYNZ) +9%. Regional Health Properties (NYSE:RHE) +9%.  Envista Holdings (NYSE:NVST) +8%. Losers: InfuSystem Holdings (NYSE:INFU) -22%. Sea...

Aeglea BioTherapeutics (NASDAQ:AGLE) withdraws its previously announced, proposed public offering. Company is capitalized with cash and cash equivalents of $95M as of December 31, 2021, which we believe will be sufficient to fund our operations into Q1 2023. For further details see: ...

Aeglea BioTherapeutics Withdraws Public Offering PR Newswire AUSTIN, Texas , Feb. 10, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme ther...

Aeglea BioTherapeutics (NASDAQ:AGLE) announced a proposed underwritten public offering of shares and, in lieu of stock, pre-funded warrants to purchase shares to certain investors. AGLE expects to grant the underwriters a 30-day option to purchase additional shares. Net proceeds, together wit...

Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency PR Newswire AUSTIN, Texas , Jan. 25, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new...

Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022 PR Newswire AUSTIN, Texas , Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of hu...

Last week was an especially rough one for several small biotechs. Disappointing news for Aeglea BioTherapeutics (NASDAQ: AGLE) , Bolt Biotherapeutics (NASDAQ: BOLT) , and Reata Pharmaceuticals (NASDAQ: RETA) caused shares of all three companies to plunge. In this ...

Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80%. BLA filing of pegzilarginase for patients with ARG1-D is expected to occur in 1st half of 2022. Additional...

Shares of Aeglea BioTherapeutics (NASDAQ: AGLE) , a clinical-stage biopharmaceutical company , are falling today in response to mixed clinical-trial data. Investors nervous about the future of the company's lead candidate pushed the stock 36.6% lower as of 11:53 a.m. ET on Monda...